YAZ / Yasmin / Ocella / Gianvi / Beyaz / Safyral / Zarah / Loryna / Syeda / Vestura
Blood Clots • Pulmonary Embolism (PE) • Deep Vein Thrombosis (DVT) • Stroke • Heart Attack • Death
March 2013 Litigation Update: As of February 12, 2013 Bayer had settlement agreements for 4,800 lawsuits, with total payment amount of $1 billion. There were 3200 blood-clot claims remaining, and new cases are still being filed.
YAZ, Yasmin, Ocella, Gianvi, Beyaz, Safyral, Zarah, Loryna, Syeda, and Vestura are birth control pills containing drospirenone (DRSP). These oral contraceptives have been associated with a possible increased risk of blood clots and potentially fatal adverse events such as deep vein thrombosis (DVT), pulmonary embolism (PE), strokes (CVA), and heart attacks or myocardial infarctions (MI).
Pradaxa
Serious Bleeding Events • Hemorrhages • Heart Attack or Myocardial Infarction (MI) • Acute Coronary Syndrome (ACS)
Pradaxa: February 2013 Update: Federal Court MDL Litigation Now Involves About 200 Lawsuits
Pradaxa is a blood-thinning drug used to reduce the risk of stroke and blood clots in people with atrial fibrillation not caused by a heart valve problem. Since coming on the market in October 2010 the FDA has received numerous Adverse Event Reports involving serious bleeding side effects such as hemorrhages. Further, medical studies have associated Pradaxa with an increased risk of heart attacks, or myocardial infarctions (MI), and acute coronary syndrome (ACS).
NuvaRing
Heart Attack • Stroke • Blood Clots • Deep Vein Thrombosis (DVT) • Pulmonary Embolism (PE)
NuvaRing Update 2013: More NuvaRing Lawsuits Filed According To Merck Report; First NuvaRing Trial Dates Moved Back (Again)
NuvaRing is a birth control product in the form of a vaginal ring containing hormones similar to those in oral contraceptives. NuvaRing has been associated with increased risk of blood clots, including deep vein thrombosis (DVT) and pulmonary embolism (PE), as well as strokes (CVA) and heart attacks or myocardial infarctions (MI).
Fosamax
Osteonecrosis of Jaw (ONJ) • Femur Fractures (Low-Stress Breaks of Thigh Bone)
First Fosamax - Femur Fracture Trial In New Jersey State Court Scheduled To Start March 11, 2013
Fosamax (alendronate), which is used to treat osteoporosis, has been associated with low-stress or atypical fractures of the femur / thigh bone. Fosamax has also been associated with osteonecrosis of the jaw, or jaw bone death, commonly referred to as ONJ.
GranuFlo
Cardiopulmonary / Cardiac Arrest • Heart Attack • Sudden Cardiac Death • Stroke (CVA) • Alkalosis
Fresenius GranuFlo Product Has Been Associated With Heart Problems And Cardiopulmonary Arrest During Dialysis Treatment
The dialysis product GranuFlo from Fresenius was used by approximately one-third of the 400,000 patients with late-stage kidney failure requiring dialysis per year at a time when Fresenius apparently knew that GranuFlo caused an increased risk of metabolic alkalosis that could result in cardiopulmonary arrest, sudden heart attack, stroke, or death.
Multaq
Liver Damage • Liver Failure • Liver Transplant • Renal Impairment • Kidney Damage • Heart Failure • Cardiovascular Death • Stroke • Institial Lung Disease (ILD) • Pulmonary Fibrosis • Pneumonitis
Multaq (dronedarone) is a drug used to treat abnormal heart rhythm (atrial fibrillation or atrial flutter). In September 2012 the FDA approved label changes for Multaq, including one about certain types of lung disease such as pneumonitis and pulmonary fibrosis being serious side effects of Multaq use. In December 2011 the FDA said Multaq increased the risk of serious cardiovascular events, including death, when used by patients in permanent atrial fibrillation (AF). In July 2011 the FDA said some clinical trial data showed a two-fold increase in death, as well as a two-fold increases in stroke (CVA) and hospitalization for heart failure in patients receiving Multaq compared to a placebo. In January 2011 the FDA issued a drug safety alert for Multaq concerning severe liver injury, such as liver failure requiring liver transplantation, associated with Multaq use. Lastly, cases of renal impairment and kidney damage in patients using Multaq have been reported.
Byetta
Pancreatitis: Acute / Hemorrhagic / Necrotizing • Kidney Failure • Renal Insuffiency
Emerging Drug Safety Issue: Possible Increased Risk Of Pancreatic Cancer With Byetta, Januvia, And Victoza -- Little Is Known About Long-Term Effects
Byetta (exenatide) is an injection drug used by adults with type 2 diabetes mellitus. This diabetes medication has been associated with damage to the pancreas -- acute pancreatitis, hemorrhagic pancreatitis, or necrotizing pancreatitis -- as well as severe kidney problems, including kidney failure and renal insufficiency.
Ketek
Liver Damage • Liver Failure • Liver Transplant
Ketek (telithromycin) is an antibiotic that has been associated with serious liver problems such as drug-induced hepatitis and liver failure, which can result in the need for a liver transplant.
All content by attorney Tom Lamb
|
Visit DrugInjuryWatch.com and see why some of attorney Tom Lamb's articles have been featured on these sites:
  
  
   
Recent Drug Injury Watch Posts
Infuse Bone Graft: Medtronic-Funded Studies Essentially Ignored Serious Medical Complications And Side Effects Associated With Its Back Surgery Product
A 2009 - 2012 Series Of Investigative Reports Published By The Milwaukee Journal Sentinel Exposed Various "Problems" With How Medtronic Went About Boosting Sales Of Infuse
SUMMARY: Reporter John Fauber, a news reporter for the Milwaukee Journal Sentinel, seems to be the journalist who should be credited most for exposing the several problematic aspects of how Medtronic has marketed its Infuse Bone Graft product over the years.
This article provides a list of such investigative reports published by the Milwaukee Journal Sentinel from 2009 to 2012, ranging from the Infuse clinical trials to serious conflicts of interest and more.
[Read this article in full at original source]
Earlier articles by attorney Tom Lamb on the Drug Injury Watch blog:
List of Latest Case Evaluations
Fosamax - Femur Fracture - 64 yr old woman (7752)
Loryna - Pulmonary Embolism (PE) and Deep Vein Thrombosis (DVT) - 44 yr old woman (7747)
Gianvi - Pulmonary Embolism (PE) and Deep Vein Thrombosis (DVT) - 21 yr old woman (7744)
Byetta - Pancreatic Cancer; Death - 71 yr old woman (7737)
Yasmin - Deep Vein Thrombosis (DVT) - 24 yr old woman (7736)
Safyral - Deep Vein Thrombosis (DVT) - 40 yr old woman (7734)
Fosamax and Boniva - Femur Fracture - 61 yr old woman (7712)
Gianvi - Deep Vein Thrombosis (DVT) with subsequent fatal Heart Attack / Myocardial
Infraction (MI) secondary to Pulmonary Embolism (PE) - 48 yr old woman (7711)
Actos - Bladder Cancer - 58 yrs old man (7698)
Syeda - Deep Vein Thrombosis (DVT) - 44 yr old woman (7692)
Gianvi - Pulmonary Embolism (PE) and Deep Vein Thrombosis (DVT) - 23 yr old woman (7691)
NuvaRing - Deep Vein Thrombosis (DVT) - 37 yr old woman (7689)
Fosamax - Femur Fracture - 80 yr old woman (7686)
Fosamax - Femur Fracture - 62 yr old woman (7685)
Safyral - Deep Vein Thrombosis (DVT) - 40 yr old woman (7681)
Fosamax - Femur Fracture - 59 yr old woman (7680)
Byetta - Kidney Failure; hospitalized 12 days, nearly died - 41 yr old man (7678)
NuvaRing - Bilateral Pulmonary Embolism (PE) - 27 yr old woman (7677)
Gianvi - Deep Vein Thrombosis (DVT) - 45 yr old woman (7673)
Zarah - Deep Vein Thrombosis (DVT); Post Thrombotic Syndrome - 30 yr old woman (7670)
Gianvi - Pulmonary Embolism (PE) and Deep Vein Thrombosis (DVT) - 38 yr old woman (7663)
Loryna - Pulmonary Embolism (PE) - 34 yr old woman (7659)
Januvia - Acute Pancreatitis - 53 yr old woman (7654)
Omontys - Hypersensitivity / Allergic Reaction And Anaphylaxis - 48 yr old woman (7649)
Loryna - Pulmonary Embolism (PE) - 21 yr old woman (7648)
Fosamax and Boniva - Bilateral Femur Fractures - 63 yr old woman (7639)
Gianvi - Pulmonary Embolism (PE) - 25 yr old woman (7636)
Ocella - Extensive Deep Vein Thrombosis (DVT); required surgery to remove clots - 28 yr old woman (7634)
Learn More About How We Work
Law Offices of Thomas J. Lamb, P.A.
Here to Help. From Start to Finish.
We know that you have options when it comes to finding the right law firm to handle your case.
On our FAQ page we provide answers to some questions prospective clients often ask us when making their decision about hiring a law firm.
|
